SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001683168-26-004050 from Sunshine Biopharma Inc. (SBFM)

Sunshine Biopharma Inc.
Date: May 18, 2026 · CIK: 0001402328 · Accession: 0001683168-26-004050

Offering / Registration Process Regulatory Compliance Business Model Clarity

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-295800

Date
May 18, 2026
Author
Robert Eide
Form
CORRESP
Company
Sunshine Biopharma Inc.

Letter

RE: SUNSHINE BIOPHARMA INC. (CIK: 0001402328)

May 18, 2026

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Registration Statement No. 333-295800 on Form S-1 (the "Registration Statement")

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the "Securities Act" ), Aegis Capital Corp. hereby requests (i) acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 11:00 a.m. Eastern Time, May 18, 2026, or as soon thereafter as practicable, and (ii) withdrawal of the previously filed request for the above-referenced Registration Statement to be declared effective May 18, 2026 at 5:00 p.m. Eastern time.

Pursuant to Rule 460 under the Securities Act, please be advised that we will distribute as many electronic copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution.

The undersigned has complied and will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

By: AEGIS CAPITAL CORP.

By: /s/ Robert Eide

Name: Robert Eide

Title: Chief Executive Officer

Show Raw Text
CORRESP
 1
 filename1.htm

 May 18, 2026

 VIA EDGAR

 Securities and Exchange Commission

 Division of Corporation Finance

 100 F Street, N.E.

 Washington, DC 20549

 RE:
 SUNSHINE BIOPHARMA INC. (CIK: 0001402328)

 Registration Statement No. 333-295800 on Form S-1 (the "Registration Statement")

 Ladies and Gentlemen:

 Pursuant to Rule 461 of the General Rules and
Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the "Securities Act" ),
Aegis Capital Corp. hereby requests (i) acceleration of the effective date of the above-referenced Registration Statement so that it will
become effective at 11:00 a.m. Eastern Time, May 18, 2026, or as soon thereafter as practicable, and (ii) withdrawal of the previously
filed request for the above-referenced Registration Statement to be declared effective May 18, 2026 at 5:00 p.m. Eastern time.

 Pursuant to Rule 460 under the Securities Act,
please be advised that we will distribute as many electronic copies of the proposed form of preliminary prospectus as appears to be reasonable
to secure adequate distribution.

 The undersigned has complied and will comply with the requirements
of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

 By:
 AEGIS CAPITAL CORP.

 By:
 /s/ Robert Eide

 Name:
 Robert Eide

 Title:
 Chief Executive Officer